GlobeNewswire Inc.··Radiopharm TheranosticsRadiopharm Theranostics Advances Novel Prostate Cancer Therapy With First Patient Dosed
Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.
RADXmonoclonal antibodyPhase 1 clinical trial